A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer

By sjmartinez • August 25, 2023

Nguyen VP, Campbell KM, Nowicki TS, Elumalai N, Medina E, Baselga-Carretero I, DiNome ML, Chang HR, Oseguera DK, Ribas A, Glaspy JA. A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer. Cancer Res Commun. 2023 Aug 23;3(8):1628-1637. doi: 10.1158/2767-9764.CRC-23-0145. PMID: 37621406; PMCID: PMC10445661.

Tags: Hematology/Oncology, Publications

Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery

Silverstein JF, Smick A, Tsui E, Alomaja O, Johnson B, Tseng CH, Salani R, Slamon DJ, Chase DM, Konecny GE. Mirvetuximab Soravtansine Exposure and Incidence[...]

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3

Nooka AK, Strouse C, Larson SM, Lesokhin A, Varshavsky-Yanovsky A, Vesole DH, Koehne G, Soussou E, Sullivan ST, Cheng J, Raje N. Efficacy and safety[...]

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma

Piperno-Neumann S, Rutkowski P, Hassel JC, Butler MO, Schlaak M, Sullivan RJ, Dummer R, Kirkwood JM, Sacco JJ, Shoushtari AN, Piulats JM, Salama AKS, Orloff[...]